Cited by 153Parathyroid Disorders and TreatmentsAtrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Fibroblast Growth Factor-23 and Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS)

Open access

Mathew, Jehu S., Sachs, Michael C., Katz, Ronit, Patton, Kristen K., Heckbert, Susan R., Hoofnagle, Andrew N., Alonso, Alvaro, Chonchol, Michel, Deo, Rajat, Ix, Joachim H., Siscovick, David S., Kestenbaum, Bryan, de Boer, Ian H.·2014·Circulation

DOI 10.1161/circulationaha.113.005499PMC PMC4108550

Open this paper in CoChat — free account

Abstract

Background—: Fibroblast growth factor-23 (FGF-23) is a hormone that promotes urinary phosphate excretion and regulates vitamin D metabolism. Circulating FGF-23 concentrations increase markedly in chronic kidney disease and are associated with increased risk of clinical cardiovascular events. FGF-23 may promote atrial fibrillation (AF) by inducing left ventricular hypertrophy and diastolic and left atrial dysfunction. Methods and Results—: We tested the associations of circulating FGF-23 concentration with incident AF among 6398 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) and 1350 participants in the Cardiovascular Health Study (CHS), all free of clinical cardiovascular disease at baseline. Over a median of 7.7 and 8.0 years of follow-up, we observed 291 and 229 incident AF events in MESA and CHS, respectively. In multivariable Cox proportional hazards models, each 2-fold-higher FGF-23 concentration was associated with a 41% higher risk of incident AF in MESA (hazard ratio, 1.41; 95% confidence interval, 1.13–1.76; P =0.003) and a 30% higher risk of incident AF in CHS (hazard ratio, 1.30; 95% confidence interval, 1.05–1.61; P =0.016) after adjustment for potential confounding characteristics, including kidney disease. Serum phosphate concentration was significantly associated with incident AF in MESA (hazard ratio, 1.15 per 0.5 mg/dL; 95% confidence interval, 1.02–1.31; P =0.023) but not CHS. In MESA, an association of low estimated glomerular filtration rate with incident AF was partially attenuated by adjustment for FGF-23. Conclusion—: Higher circulating FGF-23 concentration is associated with incident AF and may, in part, explain the link between chronic kidney disease and AF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.113.005499

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
Lang, R. M., Bierig, M., Devereux, R. B., Flachskampf, F. A., Foster, E., Pellikka, P. A., Picard, M. H., Roman, M. J., Seward, J., Shanewise, J. S., et al. (2005) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2005.10.005 · Cited by 11,318
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,226
Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Estimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027

Flagged first, then by citations

Show all 54 references

Sorted by citations

Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis
Ko, D., Rahman, F., Schnabel, R. B., Yin, X., Benjamin, E. J., & Christophersen, I. E. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.45 · Cited by 353
Roles of FGF Signals in Heart Development, Health, and Disease
Itoh, N., Ohta, H., Nakayama, Y., & Konishi, M. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00110 · Cited by 152
Role of Vitamin D in Cardiovascular Diseases
Rai, V., & Agrawal, D. K. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.07.009 · Cited by 147
FGF23 and klotho at the intersection of kidney and cardiovascular disease
Edmonston, D. L., Grabner, A., & Wolf, M. S. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00903-0 · Cited by 147
Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation
Chua, W., Purmah, Y., Cardoso, V. R., Gkoutos, G. V., Tull, S. P., Neculau, G., Thomas, M. R., Kotecha, D., Lip, G. Y. H., Kirchhof, P. F., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy815 · Cited by 140
eGFR and Albuminuria in Relation to Risk of Incident Atrial Fibrillation: A Meta-Analysis of the Jackson Heart Study, the Multi-Ethnic Study of Atherosclerosis, and the Cardiovascular Health Study.
Bansal, N., Zelnick, L. R., Alonso, Á., Benjamin, E., de Boer, I. D., Deo, R., Katz, R., Kestenbaum, B., Mathew, J. S., Robinson-Cohen, C., et al. (2017) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.01860217 · Cited by 103
Self-citation
Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome
Lekawanvijit, S. (2018) · Toxins · doi:10.3390/toxins10090352 · Cited by 122
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study
Mehta, R. C., Cai, X., Lee, J. J., Scialla, J. J., Bansal, N., Sondheimer, J., Chen, J., Hamm, L. L., Ricardo, A. C., Navaneethan, S. D., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1445 · Cited by 109
Self-citation
Fibroblast growth factor 23 is induced by an activated renin–angiotensin–aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts
Leifheit‐Nestler, M., Kirchhoff, F., Nespor, J., Richter, B., Soetje, B., Klintschar, M., Heineke, J., & Haffner, D. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy006 · Cited by 105
Atrial Fibrillation and Endothelial Dysfunction
Corban, M., Toya, T., Ahmad, A., Lerman, L. O., Lee, H.-C., & Lerman, A. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.11.005 · Cited by 87
Prevalence and Mortality of Individuals With X-Linked Hypophosphatemia: A United Kingdom Real-World Data Analysis
Hawley, S. J., Shaw, N. J., Delmestri, A., Prieto‐Alhambra, D., Cooper, C. C., Pinedo‐Villanueva, R., & Javaid, M. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz203 · Cited by 77
An Overview of FGF-23 as a Novel Candidate Biomarker of Cardiovascular Risk
Vázquez‐Sánchez, S., Poveda, J., Navarro‐García, J. A., González‐Lafuente, L., Rodríguez‐Sánchez, E., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.632260 · Cited by 74
The Multifunctional Contribution of FGF Signaling to Cardiac Development, Homeostasis, Disease and Repair
Khosravi, F., Ahmadvand, N., Bellusci, S., & Sauer, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672935 · Cited by 78
Discovery of new biomarkers for atrial fibrillation using a custom-made proteomics chip
Lind, L., Sundström, J., Stenemo, M., Hagström, E., & Ärnlöv, J. (2016) · Heart · doi:10.1136/heartjnl-2016-309764 · Cited by 72
The Atrium and Embolic Stroke
Sajeev, J., Kalman, J. M., Dewey, H. M., Cooke, J. C., & Teh, A. W. (2020) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2019.12.013 · Cited by 72
Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome
Ma, K., Gao, W., Xu, H., Liang, W., & Ma, G. (2022) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2022/3239057 · Cited by 69
Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study
Bansal, N., Xie, D., Sha, D., Appel, L. J., Deo, R., Feldman, H. I., He, J., Jamerson, K., Kusek, J. W., Messe, S. R., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050514 · Cited by 69
Self-citation
Proteomics Profiling and Risk of New‐Onset Atrial Fibrillation: Framingham Heart Study
Ko, D., Benson, M. D., Ngo, D., Yang, Q., Larson, M. G., Wang, T. J., Trinquart, L., McManus, D. D., Lubitz, S. A., Ellinor, P. T., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010976 · Cited by 67
Fibroblast Growth Factor 23 and Risk of Incident Stroke in Community-Living Adults
Panwar, B., Jenny, N. S., Howard, V. J., Wadley, V. G., Muntner, P., Kissela, B. M., Judd, S. E., & Gutiérrez, O. M. (2015) · Stroke · doi:10.1161/strokeaha.114.007489 · Cited by 65
FGF-23 and cardiovascular disease: review of literature
Batra, J., Buttar, R. S., Kaur, P., Kreimerman, J., & Melamed, M. L. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000294 · Cited by 62
Mineral metabolism and cardiovascular disease in CKD
Fujii, H., & Joki, N. (2017) · Clinical and Experimental Nephrology · doi:10.1007/s10157-016-1363-8 · Cited by 61
Coronary Endothelial Dysfunction Is Associated With Increased Risk of Incident Atrial Fibrillation
Corban, M., Godo, S., Burczak, D. R., Noseworthy, P. A., Toya, T., Lewis, B. R., Lerman, L. O., Gulati, R., & Lerman, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014850 · Cited by 61
PTH , vitamin D, and the FGF ‐23–klotho axis and heart: Going beyond the confines of nephrology
Navarro‐García, J. A., Fernández‐Velasco, M., Delgado, C., Delgado, J. F., Kuro‐o, M., Ruilope, L. M., & Ruiz‐Hurtado, G. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.12902 · Cited by 58
Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes
Navarro‐García, J. A., Delgado, C., Fernández‐Velasco, M., Val‐Blasco, A., Rodríguez‐Sánchez, E., Aceves‐Ripoll, J., Gómez‐Hurtado, N., Bada-Bosch, T., Mérida-Herrero, E., Hernández, E., et al. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy392 · Cited by 56
Coronary artery calcification: From crystal to plaque rupture
Panh, L., Lairez, O., Ruidavets, J., Galinier, M., Carrié, D., & Ferrières, J. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.04.003 · Cited by 55
The relationship between vitamin D and risk of atrial fibrillation: a dose-response analysis of observational studies
Liu, X., Wang, W. J., Tan, Z., Zhu, X., Liu, M., Wan, R., & Hong, K. (2019) · Nutrition Journal · doi:10.1186/s12937-019-0485-8 · Cited by 54
Meta‐analysis of Vitamin D Deficiency and Risk of Atrial Fibrillation
Zhang, Z., Yang, Y., Ng, C. Y., Wang, D., Wang, J., Li, G., & Liu, T. (2016) · Clinical Cardiology · doi:10.1002/clc.22563 · Cited by 53
FGF23 regulates atrial fibrosis in atrial fibrillation by mediating the STAT3 and SMAD3 pathways
Dong, Q., Li, S., Wang, W., Han, L., Xia, Z., Wu, Y., Tang, Y., Li, J., & Cheng, X. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28548 · Cited by 55
Circulating Fibroblast Growth Factor‐23 and the Incidence of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study
Alonso, Á., Misialek, J. R., Eckfeldt, J. H., Selvin, E., Coresh, J., Chen, L. Y., Soliman, E. Z., Agarwal, S. K., & Lutsey, P. L. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001082 · Cited by 51
FGF-based drug discovery: advances and challenges
Chen, G., Chen, L., Li, X., & Mohammadi, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01125-w · Cited by 51
Heart Failure and Atrial Fibrillation: From Basic Science to Clinical Practice
Ferreira, J. P., & Santos, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023133 · Cited by 47
Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation
Pol, T., Hijazi, Z., Lindbäck, J., Oldgren, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Lópes, R. D., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab262 · Cited by 45
Update on Chronic Kidney Disease Mineral and Bone Disorder in Cardiovascular Disease
Lunyera, J., & Scialla, J. J. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.08.001 · Cited by 43
Impact of Altered Mineral Metabolism on Pathological Cardiac Remodeling in Elevated Fibroblast Growth Factor 23
Leifheit‐Nestler, M., Richter, B., Basaran, M., Nespor, J., Vogt, I., Alesutan, I., Voelkl, J. G. J., Lang, F. J. W., Heineke, J., Krick, S., et al. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00333 · Cited by 42
Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease
Yan, Z., Wang, G., & Shi, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785375 · Cited by 49
Biomarkers in Atrial Fibrillation
Noubiap, J. J., Sanders, P., Nattel, S., & Lau, D. H. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.10.006 · Cited by 41
Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease
Mehta, R. C., Cho, M. E., Cai, X., Lee, J. J., Chen, J., He, J., Flack, J. M., Shafi, T., Saraf, S. L., David, V., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.07.013 · Cited by 40
Fibroblast Growth Factor 23 and Long-Term Cardiac Function
Patel, R. B., Ning, H., de Boer, I. H., Kestenbaum, B. R., Lima, J. A. C., Mehta, R. C., Allen, N. B., Shah, S. J., & Lloyd‐Jones, D. M. (2020) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.011925 · Cited by 39
Self-citation
Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis
Matkar, P. N., Ariyagunarajah, R., Leong-Poi, H. M., & Singh, K. K. (2017) · Biomolecules · doi:10.3390/biom7040074 · Cited by 39
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
Kassianides, X., & Bhandari, S. (2021) · Drugs in Context · doi:10.7573/dic.2020-11-3 · Cited by 39
Direct and indirect effects of fibroblast growth factor 23 on the heart
Nakano, T., Kishimoto, H., & Tokumoto, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1059179 · Cited by 39
Fibroblast growth factor 23 dysregulates late sodium current and calcium homeostasis with enhanced arrhythmogenesis in pulmonary vein cardiomyocytes
Huang, S.-Y., Chen, Y., Kao, Y., HSIEH, M., Lin, Y., Chung, C., Lee, T.-I., Tsai, W., Chen, S., & Chen, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12470 · Cited by 34
Clinical Potential of Targeting Fibroblast Growth Factor‐23 and αKlotho in the Treatment of Uremic Cardiomyopathy
Law, J. P., Price, A. M., Pickup, L. C., Radhakrishnan, A., Weston, C. J., Jones, A. M., McGettrick, H. M., Chua, W., Steeds, R. P., Fabritz, L., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016041 · Cited by 34
Serum 25-hydroxyvitamin D and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study
Alonso, Á., Misialek, J. R., Michos, E. D., Eckfeldt, J. H., Selvin, E., Soliman, E. Z., Chen, L. Y., Gross, M. D., & Lutsey, P. L. (2016) · EP Europace · doi:10.1093/europace/euv395 · Cited by 33
Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area
Shah, N. H., Dong, C., Elkind, M. S. V., Sacco, R. L., Mendez, A. J., Hudson, B. I., Silverberg, S. J., Wolf, M. S., Rundek, T., & Wright, C. B. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305945 · Cited by 32
Enhanced FGF23 production in mice expressing PI3K‐insensitive GSK3 is normalized by β‐blocker treatment
Fajol, A., Chen, H., Umbach, A. T., Quarles, L. D., Lang, H., & Föller, M. (2015) · The FASEB Journal · doi:10.1096/fj.15-279943 · Cited by 32
Microcalcifications, Their Genesis, Growth, and Biomechanical Stability in Fibrous Cap Rupture
Cardoso, L., & Weinbaum, S. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-96445-4_7 · Cited by 32
Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults
Nowak, K. L., Bartz, T. M., Dalrymple, L. S., de Boer, I. H., Kestenbaum, B. R., Shlipak, M. G., Garimella, P. S., Ix, J. H., & Chonchol, M. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040401 · Cited by 31
Self-citation
The changing circumstance of atrial fibrillation ‐ progress towards precision medicine
Camm, A. J., Savelieva, I., Potpara, T., Hindriks, G., Pison, L., & Blomström‐Lundqvist, C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12478 · Cited by 30
Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation
Begg, G. A., Karim, R., Oesterlein, T. G., Graham, L., Hogarth, A. J., Page, S. P., Pepper, C., Rhode, K., Lip, G. Y. H., Holden, A. V., et al. (2017) · EP Europace · doi:10.1093/europace/euw315 · Cited by 30
Phosphate and Cardiovascular Disease beyond Chronic Kidney Disease and Vascular Calcification
Disthabanchong, S. (2018) · International Journal of Nephrology · doi:10.1155/2018/3162806 · Cited by 30
Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease
Rogula, S., Gąsecka, A., Mazurek, T., Navarese, E. P., Szarpak, Ł., & Filipiak, K. J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031436 · Cited by 29
FGF23 and Nutritional Metabolism
Pool, L. R., & Wolf, M. S. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064620 · Cited by 29
Fibroblast growth factor-23 and the risk of cardiovascular diseases and mortality in the general population: A systematic review and dose-response meta-analysis
Liu, M., Xia, P., Tan, Z., Song, T., Mei, K., Wang, J., Ma, J., Jiang, Y., Zhang, J., Zhao, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.989574 · Cited by 27
The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation
Dudink, E. A. M. P. (2018) · Journal of Atrial Fibrillation · doi:10.4022/jafib.2058 · Cited by 25
The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23
Navarro‐García, J. A., Bodes, R. S., González‐Lafuente, L., Martín‐Nunes, L., Rodríguez‐Sánchez, E., Bada-Bosch, T., Hernández, E., Mérida-Herrero, E., Praga, M., Solı́s, J., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02209-9 · Cited by 24
Insights into Concomitant Atrial Fibrillation and Chronic Kidney Disease
Wang, Y., Yang, Y., & He, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303105 · Cited by 22
Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets
Navarro‐García, J. A., González‐Lafuente, L., Fernández‐Velasco, M., Ruilope, L. M., & Ruiz‐Hurtado, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.775029 · Cited by 21
Circulating biomarkers of fibrosis and cardioversion of atrial fibrillation: A prospective, controlled cohort study
Begg, G. A., Lip, G. Y. H., Plein, S., & Tayebjee, M. H. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.09.008 · Cited by 21
Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation
Mizia‐Stec, K., Wieczorek, J., Polak, M., Wybraniec, M. T., Wozniak‐Skowerska, I., Hoffmann, A., Nowak, S., Wikarek, M., Wnuk-Wojnar, A. M., Chudek, J. T., et al. (2018) · Cytokine · doi:10.1016/j.cyto.2018.08.005 · Cited by 21
Multicohort Metabolomics Analysis Discloses 9‐Decenoylcarnitine to Be Associated With Incident Atrial Fibrillation
Lind, L., Salihović, S., Sundström, J., Broeckling, C. D., Magnusson, P. K. E., Prenni, J. E., Fall, T., & Ärnlöv, J. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.017579 · Cited by 20
Relationship between serum growth differentiation factor 15, fibroblast growth factor-23 and risk of atrial fibrillation: A systematic review and meta-analysis
Tan, Z., Song, T., Huang, S., Liu, M., Ma, J., Zhang, J., Yu, P., Liu, X., & Liu, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.899667 · Cited by 20
Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients
Fusaro, M., Gallieni, M. A., Rebora, P., Rizzo, M. A., Luise, M. C., Riva, H., Bertoli, S. V., Conte, F., Stella, A., Ondei, P., et al. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0236-7 · Cited by 20
Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist’s perspective
Ravera, M., Bussalino, E., Fusaro, M., Lullo, L. D., Aucella, F., & Paoletti, E. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00720-5 · Cited by 21
Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease
Scialla, J. J. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000123 · Cited by 19
Long term evolution of endothelial function during kidney transplantation
Kensinger, C. D., Bian, A., Fairchild, M., Chen, G., Lipworth, L. P., Ikizler, T. A., & Birdwell, K. A. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0369-5 · Cited by 20
Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke
Szegedi, I., Szapáry, L. B., Csécsei, P., Csanádi, Z., & Csiba, L. (2017) · BioMed Research International · doi:10.1155/2017/8153024 · Cited by 19
Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study
Chua, W., Law, J. P., Cardoso, V. R., Purmah, Y., Neculau, G., Qamar, M. J. U., Russell, K., Turner, A., Tull, S. P., Neháj, F., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003405 · Cited by 19
New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients
Memmos, E., & Papagianni, A. A. (2020) · Current Vascular Pharmacology · doi:10.2174/1570161118666200420102100 · Cited by 18
Fibroblast growth factor 23 (FGF-23) is an early predictor of mortality in patients with cardiac arrest
Spaich, S., Zelniker, T. A., Endres, P., Stiepak, J., Uhlmann, L., Bekeredjian, R., Chorianopoulos, E., Giannitsis, E., Backs, J., Katus, H. A., et al. (2015) · Resuscitation · doi:10.1016/j.resuscitation.2015.11.012 · Cited by 18
Factors predicting the recurrence of atrial fibrillation after catheter ablation: A review
Mo, D.-G., Wang, M., Zhang, P., Dai, H., & Guan, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34205 · Cited by 17
Uromodulin associates with cardiorenal function in patients with hypertension and cardiovascular disease
Algharably, E. A. E., Bolbrinker, J., Lezius, S., Reibis, R. K., Wegscheider, K., Völler, H., & Kreutz, R. H. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001432 · Cited by 17
Fibroblast Growth Factors in Cardiovascular Disease
Morita, H., & Hoshiga, M. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv22025 · Cited by 16
Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study
Liang, Y., Luo, S., Schooling, C. M., & Yeung, S. L. A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.699455 · Cited by 16
Circulating Fibroblast Growth Factor 23 Has a U-Shaped Association With Atrial Fibrillation Prevalence
Miyamura, M., Fujita, S.-I., Morita, H., Sakane, K., Okamoto, Y., Sohmiya, K., Hoshiga, M., & Ishizaka, N. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0413 · Cited by 15
Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation
Yoshizawa, T., Niwano, S., Niwano, H., Tamaki, H., Nakamura, H. K., Igarashi, T., Oikawa, J., Satoh, A., Kishihara, J., Murakami, M., et al. (2018) · International Heart Journal · doi:10.1536/ihj.17-391 · Cited by 15
Mechanisms underlying atrial fibrillation in chronic kidney disease
Navarro‐García, J. A., Keefe, J. A., Song, J., Li, N., & Wehrens, X. H. T. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.06.002 · Cited by 14
Circulating adipose tissue proteins involved in atrial fibrillation: An explorative scoping review
Meulendijks, E. R., Krul, S. P. J., Baalman, S. W. E., de Vries, T. A. C., Wesselink, R., Ernault, A. C., Kawasaki, M., Al‐Shama, R., Neefs, J., Limpens, J., et al. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.12.004 · Cited by 14
Associations of Circulating Vascular Cell Adhesion Molecule‐1 and Intercellular Adhesion Molecule‐1 With Long‐Term Cardiac Function
Mathew, D. T., Peigh, G., Lima, J. A. C., Bielinski, S. J., Larson, N. B., Allison, M., Shah, S. J., & Patel, R. B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032213 · Cited by 14
Biomarkers of Key Biological Pathways in CVD
Jenny, N. S., Olson, N. C., Allison, M., Rifkin, D. E., Daniels, L. B., de Boer, I. H., Wassel, C. L., & Tracy, R. P. (2016) · Global Heart · doi:10.1016/j.gheart.2016.07.003 · Cited by 14
Longitudinal assessment of cardiac morphology and function following kidney transplantation
Kensinger, C. D., Hernandez, A., Bian, A., Fairchild, M., Chen, G., Lipworth, L. P., Ikizler, T. A., & Birdwell, K. A. (2016) · Clinical Transplantation · doi:10.1111/ctr.12864 · Cited by 14
Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
Rago, A., Pirozzi, C., D’Andrea, A., Micco, P. D., Papa, A. A., D’Onofrio, A., Golino, P., Nigro, G., & Russo, V. (2023) · Medicina · doi:10.3390/medicina59020254 · Cited by 13
Electrocardiogram findings at the initiation of hemodialysis and types of subsequent cardiovascular events
Yamaguchi, S., Hamano, T., Oka, T., Doi, Y., Kajimoto, S., Yasuda, S., Shimada, K., Matsumoto, A., Sakaguchi, Y., Inoue, K., et al. (2021) · Hypertension Research · doi:10.1038/s41440-020-00592-z · Cited by 13
The Status and Research Progress on Vitamin D Deficiency and Atrial Fibrillation
Bie, L. (2019) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2018-0322 · Cited by 13
Individualized acute kidney injury after care
Koyner, J. L., Haines, R. W., & Bouchard, J. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000779 · Cited by 13
Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study
Mehta, R. C., Ying, G. S., Houston, S. K. S., Isakova, T., Nessel, L. C., OJO, A. O., Go, A. S., Lash, J., Kusek, J. W., Grunwald, J. E., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv123 · Cited by 12
Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: a randomized, open-labeled clinical trial
Han, N., Hong, S. H., Kim, Y. S., Kim, D. K., Kim, I., Ji, E., & Oh, J. M. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s142564 · Cited by 12
Sex-specific contemporary trends in incidence, prevalence and survival of patients with non-valvular atrial fibrillation: A long-term real-world data analysis
Shiyovich, A., Chodick, G., Azani, L., Tirosh, M., Shuvy, M., Pereg, D., Katz, A., & Minha, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247097 · Cited by 12
Associations between endogenous sex hormones and FGF-23 among women and men in the Multi-Ethnic Study of Atherosclerosis
Ogunmoroti, O., Osibogun, O. I., Zhao, D., Mehta, R. C., Ouyang, P., Lutsey, P. L., Robinson‐Cohen, C., & Michos, E. D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268759 · Cited by 12
Mineral metabolism in heart disease
Heine, G. H. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000129 · Cited by 12
Association between Heat Shock Protein‐60 and Development of Atrial Fibrillation: Results from the Multi‐Ethnic Study of Atherosclerosis (MESA)
Maan, A., Jorgensen, N. W., Mansour, M., Dudley, S. C., Jenny, N. S., deFilippi, C. R., Szklo, M., Alonso, Á., Refaat, M. M., Ruskin, J. N., et al. (2016) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12969 · Cited by 12
Self-citation
Impact of gender on left atrial low-voltage zones in patients with persistent atrial fibrillation: results of a voltage-guided ablation
Marzak, H., Ringele, R., Matsushita, K., Marchandot, B., Fitouchi, S., Cardi, T., Kanso, M., Schatz, A., Hammann, J., Ohlmann, P., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1229345 · Cited by 11
The endocrine FGFs axis: A systemic anti-fibrotic response that could prevent pulmonary fibrogenesis?
Ghanem, M., Archer, G., Crestani, B., & Mailleux, A. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108669 · Cited by 12
Evaluation of Atrial Fibrosis in Atrial Fibrillation Patients with Three Different Methods
Çöteli, C., Hazırolan, T., Aytemir, K., Erdemir, A. G., BAKIR, E. N., Canpolat, U., Yorgun, H., Ateş, A. H., Kaya, E. B., Dikmen, Z. G., et al. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2103-194 · Cited by 11
Fibroblast growth factor-23 is independently associated with cardiac mass in African-American adolescent males
Falkner, B. E., Keith, S. W., Gidding, S. S., & Langman, C. B. (2017) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2017.04.001 · Cited by 11
Vitamin D, vitamin D supplementation and atrial fibrillation risk in the general population: updated systematic review and meta-analysis of prospective studies
Ding, X., Lai, J., Zhang, H., & Guo, Z. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1246359 · Cited by 11
The Effects of Storage Time and Repeated Freeze–Thaw Cycles on Intact Fibroblast Growth Factor 23 Levels
Tang, R., Lu, Y., Yin, R., Zhu, P., Zhu, L., & Zheng, C. (2020) · Biopreservation and Biobanking · doi:10.1089/bio.2020.0073 · Cited by 9
Elevated fibroblast growth factor-23 and risk of cardiovascular disease or mortality in the general population: A meta-analysis
Jiang, M., Gong, D., & Fan, Y. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.276 · Cited by 9
Left atrial deformation as a potent predictor for paroxysmal atrial fibrillation in patients with end-stage renal disease
Papadopoulos, C. E., Pagourelias, E. D., Bakogiannis, C., Triantafyllou, K., Baltoumas, K., Kassimatis, E., Zioutas, D., Siskos, D., Tzikas, S., Fragakis, N., et al. (2018) · International journal of cardiac imaging · doi:10.1007/s10554-018-1353-x · Cited by 9
Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)
Siegbahn, A. G., Eriksson, N., Assarsson, E., Lundberg, M., Ballagi, A., Held, C., Stewart, R., White, H. D., Åberg, M., & Wallentin, L. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293465 · Cited by 9

Authors: Mathew, J. S., Sachs, M. C., Katz, R., Patton, K. K., Heckbert, S. R., Hoofnagle, A. N., Alonso, A., Chonchol, M., Deo, R., Ix, J. H., Siscovick, D. S., Kestenbaum, B., & de Boer, I. H.
Affiliations: University of Minnesota (US)
From the Division of Cardiology (J.S.M., K.K.P.), Division of Nephrology and Kidney Research Institute (J.S.M., M.C.S., R.K., B.K., I.H.d.B.), Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology (S.R.H., D.S.S.), Department of Epidemiology (S.R.H., B.K., I.H.d.B.), and Department of Laboratory Medicine (A.N.H.), University of Washington, Seattle; Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis (A.A.); Division of...
ORCID: Sachs, Michael C.
Katz, Ronit
Patton, Kristen K.
Heckbert, Susan R.
Hoofnagle, Andrew N.
Chonchol, Michel
Deo, Rajat
Ix, Joachim H.
Siscovick, David S.
Kestenbaum, Bryan
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2014-07-22
Volume: 130
Issue: 4
Pages: 298-307
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.113.005499
PMC: PMC4108550
OpenAlex: W2114238925
Cited by: 153
References: 54
Citations by year: 2026: 9 · 2025: 7 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 18 · 2020: 11 · 2019: 7 · 2018: 18 · 2017: 12 · 2016: 19 · 2015: 12 · 2014: 5
FWCI: 12.65
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (n01hc085082-026, n01hc085081-021, n01hc085079-024, n01hc085083-027, n01hc085080-026, n01hc095169-003, n01hc085086-022, n01hc55222-0-0-0, n01hc95159-40-0-1)
National Institute on Aging (R56AG023629, AG023629, R01AG023629)
National Heart, Lung, and Blood Institute (N01 HC085086, R01HL096875, N01-HC095169, N01 HC085079, N01 HC085083, N01 HC085080, N01-HC-095159, R01HL102214, N01HC085082, N01 HC055222, N01 HC085081, R01HL080295)
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK035816)
National Center for Research Resources (UL1RR024156, UL1RR025005)
Topics: Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: fibroblast growth factor 23, atrial fibrillation, chronic kidney disease, serum phosphorus, vitamin D metabolism, left atrial dysfunction, left ventricular hypertrophy, estimated glomerular filtration rate, cardiovascular risk factors
MeSH terms: Fibroblast Growth Factor-23, Aged, Aged, 80 and over, Atrial Fibrillation, Ethnicity, Female, Follow-Up Studies, Glomerular Filtration Rate, Heart Failure, Humans, Male, Middle Aged, Phosphates, Risk Factors, United States, Vitamin D, Comorbidity, Proportional Hazards Models, Hypertrophy, Left Ventricular, Ventricular Dysfunction, Left, Ventricular Remodeling, Renal Insufficiency, Chronic, Fibroblast Growth Factor 3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fibroblast Growth Factor-23 and Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks